About Us

PHARMACEUTICAL RESEARCH

We are a pharmaceutical company with headquarters in Barcelona specialized in research and development activities of high-tech pharmaceutical products for the oncology field, with an specific focus on the treatment of breakthrough pain in cancer patients.

BUSINESS DEVELOPMENT

We out-license our highly specialized products to pharmaceutical partners for their commercialization around the world, helping them to increase their R&D capacity and expanding their portfolios that require this specific technology.

QUALITY AND SAFETY

Proteus Pharma complies with the highest quality and regulations requirements and its facilities have the latest manufacturing technology, ensuring quality and safety standards worldwide.

Description

Oral Tansmucosal Fentanyl Citrate with integral applicator is indicated for the management of breakthrough pain (BTP) in cancer patients who are already receiving opioid therapy for their underlying persistent cancer pain.



tick-02Doses: 200 –> 400 –> 600 –> 800 –> 1200 –> 1600 mcg

tick-02Reference product: ACTIQ® (CEPHALON/ TEVA)

tick-02Unit size: Individual units supplied in blisters of 3/15/30 units

tick-02Primary packaging: Each dosage unit is contained in a heat sealed blister package consisting of a paper/foil laminated lid, and a PVC/Aclar thermoformed blister.

tick-02Manufacturing site: GMP-plant based in Barcelona


Download product card

Galenic Technology

OTFC is the only fentanyl citrate available in a sweetener matrix, set in a stick, which facilitates absorption of fentanyl through the oral mucosa, in a constant form, by dissolving slowly in the mouth.
It is the only one controlled by the patient.

1st differentiating element from the rest of fentanyl options:

THE PATIENTS THEMSELVES CAN CONTROL THEIR PAIN MANAGEMENT

Key points and Advantages

  • Rapid

    OTFC permits constant fentanyl absorption, so that the plasma peak appears early, but not suddenly (effective and safe).

  • Controllable

    OTFC is the only patient self-controlled treatment: optimum safety/efficacy benefit.

  • Safe

    Higher safety profile due to the innovative applicator that avoids sobredosification.

  • Effective

    Better patient compliance and overall efficacy.

  • Easy to use

    Convenience in administration.

  • Innovator

    There is extensive literature on OTFC in BTP, showing that it is significantly better in terms of SPEED and POTENCY than conventional treatment (including short-acting opiods).

Contact Us

Universidad Autónoma, 13 – 08290 Cerdanyola del Vallès (Barcelona)
T. +34 948 101 943
sazon@proteuspharma.com

    adminHome – One Page Style